An anti-CD30 antibody–drug conjugate consisting of a CD30-directed IgG1 monoclonal antibody linked to the cytotoxic payload monomethyl auristatin E (MMAE). It binds CD30 on tumor cells, is internalized, and releases MMAE intracellularly to inhibit microtubules, leading to G2/M arrest and apoptosis; may also mediate ADCC and bystander cytotoxicity.
CD30-directed IgG1 antibody-drug conjugate; binds CD30 on tumor cells and is internalized. Lysosomal proteases cleave the valine-citrulline linker to release MMAE, which inhibits tubulin polymerization, causing G2/M cell-cycle arrest and apoptosis; may also elicit ADCC and bystander cytotoxicity.
NO
INDIRECT
The ADC binds CD30 (not beta-tubulin), is internalized, and releases MMAE, which inhibits beta-tubulin polymerization to cause G2/M arrest and apoptosis. Beta-tubulin expression alone does not make cells targets for killing.
Autologous adoptive T-cell therapy consisting of ex vivo expanded, tumor‑reactive T lymphocytes harvested from tumor‑draining lymph nodes; administered after lymphodepletion to mediate antigen-specific cytotoxicity.
Autologous tumor‑reactive T lymphocytes harvested from tumor‑draining lymph nodes are expanded ex vivo and reinfused after lymphodepletion. These unengineered T cells recognize tumor antigens via their native TCRs in an MHC‑restricted manner, expand (with IL‑2 support), and mediate antigen‑specific cytotoxicity through perforin/granzyme release and cytokine production to eliminate tumor cells.
YES
DIRECT
Infused tumor‑reactive T cells recognize the neoantigen peptide–HLA class I complex via native TCRs and directly kill target cells through cytolytic synapse formation with perforin/granzyme–mediated apoptosis (and Fas–FasL pathways).
Autologous adoptive T-cell therapy consisting of ex vivo expanded, tumor‑reactive T lymphocytes harvested from tumor‑draining lymph nodes; administered after lymphodepletion to mediate antigen-specific cytotoxicity.
Autologous tumor‑reactive T lymphocytes harvested from tumor‑draining lymph nodes are expanded ex vivo and reinfused after lymphodepletion. These unengineered T cells recognize tumor antigens via their native TCRs in an MHC‑restricted manner, expand (with IL‑2 support), and mediate antigen‑specific cytotoxicity through perforin/granzyme release and cytokine production to eliminate tumor cells.
YES
DIRECT
Adoptively transferred tumor‑reactive T cells recognize the neoantigen peptide–HLA class II complex via their native TCRs and directly lyse the presenting cell through perforin/granzyme release (± Fas–FasL), with supportive cytokine effects.
Autologous adoptive T-cell therapy consisting of ex vivo expanded, tumor‑reactive T lymphocytes harvested from tumor‑draining lymph nodes; administered after lymphodepletion to mediate antigen-specific cytotoxicity.
Autologous tumor‑reactive T lymphocytes harvested from tumor‑draining lymph nodes are expanded ex vivo and reinfused after lymphodepletion. These unengineered T cells recognize tumor antigens via their native TCRs in an MHC‑restricted manner, expand (with IL‑2 support), and mediate antigen‑specific cytotoxicity through perforin/granzyme release and cytokine production to eliminate tumor cells.
YES
DIRECT
Infused tumor-reactive T cells recognize the tumor-associated peptide–HLA class I complex via their native TCRs and directly kill the presenting cell through perforin/granzyme-mediated apoptosis (± Fas–FasL).
Autologous adoptive T-cell therapy consisting of ex vivo expanded, tumor‑reactive T lymphocytes harvested from tumor‑draining lymph nodes; administered after lymphodepletion to mediate antigen-specific cytotoxicity.
Autologous tumor‑reactive T lymphocytes harvested from tumor‑draining lymph nodes are expanded ex vivo and reinfused after lymphodepletion. These unengineered T cells recognize tumor antigens via their native TCRs in an MHC‑restricted manner, expand (with IL‑2 support), and mediate antigen‑specific cytotoxicity through perforin/granzyme release and cytokine production to eliminate tumor cells.
YES
DIRECT
Tumor-reactive T cells recognize the specific tumor peptide–HLA class II complex via their native TCRs and directly kill target cells through perforin/granzyme release and Fas–FasL–mediated apoptosis.